ASX:NEUPharmaceuticals
Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns
Neuren Pharmaceuticals (ASX:NEU) has opened FY 2025 with first half revenue of A$28.3 million and basic EPS of A$0.12, setting a different tone from the prior half, when the company recorded A$192.5 million of revenue and basic EPS of A$1.05. The company has seen revenue move from A$26.2 million and basic EPS of A$0.06 in the first half of FY 2024 to A$28.3 million and A$0.12 in the latest period. Trailing twelve month EPS sits at A$1.17 on revenue of A$218.9 million, giving investors a clear...